Risk Reward Update

研报英文原文证据摘录

Not for redistribution without written consent of Morgan Stanley

M

Update

August 7, 2026 08:44 PM GMT

Charles River Laboratories International | North

America

Morgan Stanley & Co. LLC

Kallum L Titchmarsh

Equity Analyst

Risk Reward Update

What’s Changed

Updated Components

EPS

Bull Base Bear Scenarios

Risks to Price Target / Rating

Risk Reward for Charles River Laboratories International (CRL.N)

has been updated

Reason for change

Charles River Laboratories International (CRL.N, CRL UN)

Life Science Tools & Diagnostics | United States of

America

Stock Rating

Industry View

Price target

Shr price, close (Aug 6, 2026)

52-Week Range

Overweight

In-Line

$300.00

$265.51

$267.23-144.30

Fiscal Year Ending

12/25 12/26e 12/27e 12/28e

EPS ($)**

Prior EPS ($)**

10.29

11.34

12.90

14.22

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare

framework

** = Based on consensus methodology

e = Morgan Stanley Research estimates

We updated our CRL model following Q2 2026 earnings results

Morgan Stanley does and seeks to do business with

companies covered in Morgan Stanley Research. As a result,

investors should be aware that the firm may have a conflict of

interest that could affect the objectivity of Morgan Stanley

Research. Investors should consider Morgan Stanley

Research as only a single factor in making their investment

decision.